NASDAQ$NUTX
Nutex Health Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close
Briefing
Nutex Health reported Q3 2025 total revenue of $267.8M with net income attributable to the company of $55.4M.
Total revenue was $267.8 million versus $78.8 million a year ago, led by the hospital division at $260.2 million. Net income attributable to Nutex Health was $55.4 million compared to a net loss of $8.8 million in Q3 2024. Nine-month revenue reached $723.6 million with net income of $59.0 million attributable to shareholders.
- Q3 total revenue $267.8M; hospital division $260.2M.
- Net income attributable to Nutex $55.4M vs prior-year loss.
- Population health management revenue $7.6M.
- Scale-up from hospital acquisitions drove YoY growth.
Headline financials
Revenue & EPS history
Nutex Health Inc · Revenue · Quarterly
$268M
Revenue by segment
Nutex Health Inc · $244M total across 2 segments · Q2 2025
- Hospital Division$236M—96.9%
- Population Health Management$7.68M—3.1%
Forward guidance
Hospital roll-up strategy drives scale; integration and payer mix remain focal points.
Tailwinds
- Hospital division revenue scale.
- Turnaround to profitability on acquired assets.
Headwinds
- Regulatory and reimbursement risk.
- Integration and leverage from rapid growth.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2025
+1.9%
Avg return
Earnings day
+17.2%
Avg return
5 days after
+21.1%
Avg return
30 days after
62%
8 / 13 earnings
Positive
+22.4%
Q1 2022
Best reaction
-14.3%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +6.4% | +8.0% | +14.4% | |
| Q4 2025 | -14.3% | -14.1% | -4.2% | |
| Q3 2025 | +0.0% | +32.9% | +64.1% | |
| Q1 2025 | +1.0% | +40.2% | +0.2% | |
| Q3 2024 | +6.3% | +38.2% | +39.3% | |
| Q2 2024 | +0.9% | +62.7% | +173.1% | |
| Q1 2024 | +6.2% | +14.8% | +0.7% | |
| Q3 2023 | +0.0% | -6.0% | -22.8% | |
| Q2 2023 | +3.6% | +0.9% | -20.1% | |
| Q1 2023 | +8.9% | +10.3% | -17.8% | |
| Q3 2022 | -9.2% | +1.7% | +59.7% | |
| Q2 2022 | -8.2% | -27.9% | -53.8% | |
| Q1 2022 | +22.4% | +61.8% | +41.2% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro